Atricure, Inc. is a healthcare company based in the United States that specializes in innovative surgical treatments and therapies for conditions such as atrial fibrillation (Afib) and left atrial appendage (LAA) management. With a focus on ESG principles, Atricure offers products like Cryo, Soft Tissue Dissection, and RF Ablation Pacing to medical centers through direct sales and distributors. The company also provides minimally invasive ablation devices to support less invasive cardiac and thoracic surgery. Atricure operates with a medium risk rating score of 22.8, reflecting its commitment to sustainability and governance.